GLP-1受体激活剂在管理癌症治疗相关心脏功能障碍中的作用
Aravinthan Vignarajah1, San Kim1, Moath Albliwi1
1Department of Medicine Cleveland Clinic Fairview Hospital Cleveland OH USA.
Journal of the American Heart Association
|November 6, 2025
概括
类似葡萄糖类-1受体激动剂 (GLP-1RA) 可能改善癌症患者的存活率和心力衰竭结果与癌症治疗相关的心脏功能障碍 (CTRCD). 这项研究表明,GLP-1 RA的使用与心力衰竭治疗中CTRCD患者的更好的结果有关.
科学领域:
- 心脏病学 心脏病学
- 在瘤学瘤学.
- 药理学 药理学是指药理学的学科.
背景情况:
- 癌症治疗可以导致心脏功能障碍 (CTRCD).
- 类似葡萄糖-1受体激动剂 (GLP-1RA) 显示出心脏保护作用.
- GLP-1 RAs在CTRCD中的作用尚未得到充分证实.
研究的目的:
- 调查GLP-1 RA使用对CTRCD患者结局的影响.
- 为了评估GLP-1 RA治疗与死亡率,心力衰竭恶化和CTRCD患者住院治疗之间的关联.
主要方法:
- 使用TriNetX研究网络进行的回顾性队列研究.
- 包括有癌症病史,抗瘤疗法和CTRCD (2012-2023) 的成年人.
- 倾向性得分匹配 (1:1) 对比GLP-1RA使用者和非使用者在1年内为心力衰竭进行指导方针导向的医疗治疗.
主要成果:
- 与非使用者相比,GLP-1 RA使用者 (n=837) 的全因死亡率 (HR 0.57),急性心力衰竭恶化 (HR 0.69) 和全因住院 (HR 0.83) 显著降低.
- 观测到心房动/动和腹腔动心率的减少,但没有统计学意义.
- 该队列包括4982名患有CTRCD的患者,其中837人接受GLP-1 RA治疗.
结论:
- 在接受指导方针导向药物治疗的CTRCD患者中使用GLP-1 RA可能与1年生存率的改善有关.
- 在这种患者群体中,GLP-1 RA治疗似乎与更好的心力衰竭相关结果有关.
相关概念视频
Glucagon-like Receptor Agonists
828
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
828
Oral Hypoglycemic Agents: Biguanides and Glitazones
568
Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
568
Transducer Mechanism: Enzyme-Linked Receptors
3.8K
Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include:
Major types that are helpful drug targets include:
3.8K
Oral Hypoglycemic Agents: α-Glucosidase Inhibitors
511
α-glucosidase inhibitors, including acarbose (Precose), miglitol (Glyset), and voglibose (Voglib) (primarily available in Asia), are drugs that control blood sugar levels by delaying the digestion of starch and disaccharides. They achieve this by inhibiting α-glucosidase enzymes in the intestine, which slow the absorption of carbohydrates in the intestine, which in turn leads to a prolonged release of the glucoregulatory hormone GLP-1 from intestinal L-cells.
Acarbose and miglitol are...
Acarbose and miglitol are...
511
Dipeptidyl Peptidase 4 Inhibitors
570
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
570
G Protein-coupled Receptors
16.4K
G Protein-Coupled Receptors or GPCRs are membrane-bound receptors that transiently associate with heterotrimeric G proteins and induce an appropriate response to sensory stimuli such as light, odors, hormones, cytokines, or neurotransmitters.
GPCRs are also called heptahelical, 7TM, or serpentine receptors, and consist of seven (H1-H7) transmembrane alpha-helices that span the bilayer to form a cylindrical core. The transmembrane helices are connected by three extracellular loops and three...
GPCRs are also called heptahelical, 7TM, or serpentine receptors, and consist of seven (H1-H7) transmembrane alpha-helices that span the bilayer to form a cylindrical core. The transmembrane helices are connected by three extracellular loops and three...
16.4K

